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2 CHEN ET ALBackground: Patients with heterozygous germline mutations in
phosphatase and tensin homolog deleted on chromosome 10
(PTEN) experience autoimmunity and lymphoid hyperplasia.
Objectives: Because regulation of the phosphoinositide 3-kinase
(PI3K) pathway is critical for maintaining regulatory T (Treg)
cell functions, we investigate Treg cells in patients with
heterozygous germline PTEN mutations (PTEN hamartoma
tumor syndrome [PHTS]).
Methods: Patients with PHTS were assessed for immunologic
conditions, lymphocyte subsets, forkhead box P3 (FOXP3)1 Treg
cell levels, and phenotype. To determine the functional importance
of phosphatases that control the PI3K pathway, we assessed Treg
cell induction in vitro, mitochondrial depolarization, and
recruitment of PTEN to the immunologic synapse.
Results: Autoimmunity and peripheral lymphoid hyperplasia
were found in 43% of 79 patients with PHTS. Immune
dysregulation in patients with PHTS included lymphopenia,
CD41 T-cell reduction, and changes in T- and B-cell subsets.
Although total CD41FOXP31 Treg cell numbers are reduced,
frequencies are maintained in the blood and intestine. Despite
pathogenic PTEN mutations, the FOXP31 T cells are
phenotypically normal. We show that the phosphatase PH
domain leucine-rich repeat protein phosphatase (PHLPP)
downstream of PTEN is highly expressed in normal human Treg
cells and provides complementary phosphatase activity. PHLPP
is indispensable for the differentiation of induced Treg cells
in vitro and Treg cell mitochondrial fitness. PTEN and PHLPP
form a phosphatase network that is polarized at the
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Generation of the second messenger phosphatidylinositol-
3,4,5-trisphosphate by phosphoinositide 3-kinase (PI3K) consti-
tutes a critical checkpoint for immune activation.1 This pathway
is controlled by phosphatases, such as PTEN, a dual-specific pro-
tein and lipid phosphatase. Pten deletion in immune cell subsets
in mice caused defects in T cells,2,3 CD41Foxp31 regulatory T
(Treg) cells4-6 and B cells.7 Heterozygous Pten deletion caused
autoimmunity, intestinal lymphoid hyperplasia, thymus hyperpla-
sia, and thymoma and T-cell lymphoma formation.8,9
Heterozygous PTEN mutations are found in a group of
hereditary disorders known as PTEN hamartoma tumor syndrome
(PHTS).10 Patients with PHTS can present with autoimmunity,
lymphoid hyperplasia, colitis and lymphopenia, as well as defects
in B cell responses11,12 and low immunoglobulin levels.11,13
The PI3K/AKT/mammalian target of rapamycin (mTOR)
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some 10SHIP: Src homology domain 2–containing inositol phosphataseTCR: T-cell receptorTmem: Memory TTMRE: Tetramethylrhodamine-ethylesterhomeostasis.5,6,14-18 This pathway is activated downstream of the
T-cell receptor (TCR), CD28, and IL-2 signaling. It is critically
involved in Treg cell thymic development, peripheral expansion,
and suppressive activity.18 Constitutively active Akt impairs
CD41Foxp31T-cell differentiation in the thymusbut does not affect
established Foxp3 expression in Treg cells.14 Akt inhibits the FoxO
family of transcription factors, FoxO1 and FoxO3a, which direct
both Foxp3-dependent and independent suppressive programs in
Treg cells.19-22 The metabolic checkpoint kinase mTOR orches-
trates Treg cell metabolic programs and suppressive function.23,24
Although mTOR activity is critical for differentiation into TH1
and TH2 lineages and TH17 lineage commitment, TCR engagement
in the absence of mTOR leads to Treg cell differentiation.17 These
observations highlight the importance of a stringent negative regula-
tion of PI3K pathway activity in Treg cells.
We describe immune dysregulation in patients with PHTS. We
expected that because of increased PI3K/AKT signaling, Treg cell
generation and stability would be affected. However, we detected
no abnormal accumulation of these cells. Instead, we identified a
phosphatase network in which the phosphatase PH domain
leucine-rich repeat protein phosphatase (PHLPP) acts as an
essential phosphatase downstream of PTEN, thereby preventing
excessive AKT activation in Treg cells, and provides functional
complementation for PTEN. We show that PTEN and PHLPP act
to sustain mitochondrial metabolism in Treg cells. PTEN and
PHLPP form a phosphatase network supported by the scaffold
protein Na1/H1-exchanger 3 regulatory factor (NHERF1),
allowing polarization of phosphatase activity toward the immuno-
logic synapse in Treg cells. This polarized network might allow
maintenance of Treg cell function through coordinated phospha-
tase activities to restrain phospho-AKT accumulation.METHODS
Patients, material, and clinical methods
Seventy-nine patients with pathogenic germline PTEN mutations were
enrolled in the study (39 male and 40 female patients; Fig 1, A, and see Tables
E1 and E2 in this article’s Online Repository at www.jacionline.org). Ethical re-
viewwas granted by the institutional ethical review boards (Leipzig, Bonn, Frei-
burg and Oxford Universities and the Cleveland Clinic). Control blood samples
were obtained from healthy volunteer donors or as leukocyte cones from a
United Kingdom blood donor bank. Patients’ biopsy specimens were derived
from routine endoscopies and noninflammatory mucosa-associated lymphoid
tissue (MALT) control tissues after appendectomy (n5 10). Written informed
consent was obtained for all patients and control subjects.
Immunohistochemistry and fluorescence
microscopy
Paraffin-embedded biopsy specimens were used for immunohistochem-
istry by using multicolor fluorescence staining and tyramide amplification,
essentially as described previously11 and specified in the Methods section in
this article’s Online Repository at www.jacionline.org. Fluorescence images
were recorded with a Keyence BZ-8000 (Keyence, Osaka, Japan) or Zeiss Ax-
ioscope (Zeiss, Oberkochen, Germany) fluorescence microscope.
Flow cytometry
Leukocyte subsets from patients with PHTS and healthy control subjects were
analyzed by using fluorescence-activated cell sorting (FACS; as specified in the
Methods section in this article’s Online Repository). Treg cells from blood were
detected by means of intracellular staining for forkhead box P3 (FOXP3;
Foxp3/Transcription Factor Staining Buffer Set; eBioscience, San Diego, Calif)
and/or the cell-surface markers CD127, CD25, and CD4, as indicated. Intracel-
lular staining was performed for PTEN (clone Y184; Epitomics, Burlingame,
Calif), cytotoxicT lymphocyte–associated antigen4 (CTLA-4; clone 14D3, eBio-
science), andHelios (clone 22F6;MiltenyiBiotec,BergischGladbach,Germany).
Phosflowwas performed on PBMCs from healthy donors after preincubation
for 5 minutes with biotinylated anti-CD3 (clone OKT3; BioLegend, San Diego,
Calif) and anti-CD28 (cloneCD28.2, eBioscience; eachat 3.3mg/mL in150mL)
and activation by avidin (150mL of 50mg/mL; Invitrogen, Carlsbad, Calif) and
IL-2 (500 IU/mL; PeproTech, Rocky Hill, NJ). Cells were stained 10 minutes
after activation with anti-phosphorylated signal transducer and activator of
transcription 5 (pY694, clone 47), anti-pAKT (pS473, cloneM-89-61), and anti-
pS6 (pS235/p236, clone N7-548) by using BD Biosciences Phosflow reagents
and analyzed on the LSR II instrument (BD Biosciences, San Jose, Calif). All
FACS analyses were performedwith FlowJo software (TreeStar, Ashland, Ore).
Tetramethylrhodamine-ethylester assay
Fresh PBMCs were cultured for 20 hours in the presence of low
(0.4 mmol/L), medium (2 mmol/L; inhibitory concentration of 50% [IC50]),
or high (4 mmol/L) concentrations of the PTEN inhibitor SF1670 (Cellagen
Technology, San Diego, Calif) alone or in combination with the PHLPP in-
hibitor (US NCI, NCS 45586; IC50, 70 mmol/L) to investigate the effects
of PTEN/PHLPP inhibitors. Cells were then stimulated with T-cell activator
beads (1 bead to 1 CD41 T cell for 90 minutes). The tetramethylrhodamine-
ethylester (TMRE; ab113852; Abcam, Cambridge, United Kingdom) assay
was performed, according to the manufacturer’s protocol. TMRE staining
was combined with CD41, CD25, and CD127 surface staining.
PBMCs were cultured for 20 hours and stained with indicated surface
marker antibodies and TMRE to measure mitochondrial membrane potential
to compare control subjects with patients with PHTS.PTEN, PHLPP, and NHERF1 recruitment to the
immunologic synapse
Preparation of supported planar bilayer was described previously.25-27
The bilayers were then blocked with casein and incubated with streptavidin
(5 mg/mL), monobiotinylated OKT3 labeled with Alexa Flour 647 (4 mg/mL),
FIG 1. PHTS patient cohort and clinical phenotype. A, Representation of different pathogenic germline
PTEN mutations in 79 patients with PHTS investigated. Symbols represent the mutation site of individual
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CHEN ET AL 5ICAM1-12xHis labeled with Alexa Fluor 405 (200 mol/mm2). CD41CD251
T cells (13 106) were injected into prewarmed chambers. Anti-PHLPP (against
peptides 1596-1610; Sigma, St Louis, Mo), anti-NHERF1 (against a peptide
around alanine 310; Cell Signaling, Danvers, Mass), and anti-PTEN (D4.3,
Cell Signaling) were detected by using donkey anti-rabbit F(ab9)2 fragments
labeled with Alexa Fluor 488 (Jackson Laboratories, Bar Harbor, Me).
CD41CD251 cells were rested overnight before analysis. LabTek II chambers
(Thermo Scientific, Waltham, Mass) were coated with OKT3 (BioXCell, West
Lebanon, NH) at 10 mg/mL and intercellular adhesion molecule 1 (ICAM-1)
at 1 mg/mL. Briefly, 53 105 cells were added to chambers coated with OKT3
and ICAM-1 for 5, 15, or 30 minutes at 378C. Then the cells were fixed with
2% paraformaldehyde in PHEM buffer, permeabilized with 0.1% Triton-X100
for 5 minutes at room temperature, blocked with casein, and incubated with pri-
mary antibodies for 1 hour at room temperature in 2% donkey serum. Finally,
cells were incubatedwith secondary antibodies (1:250) andmounted in antifade
reagent (SlowFade Gold, Invitrogen). Control samples of secondary antibodies
alone were included in each experiment. Imaging was performed by using a
ZeissLSM710 confocal laser-scanningmicroscopewith a3631.4NAobjective
to study time-dependent recruitment of proteins. Image analysis and 3-
dimensional reconstruction was performed with ImageJ software (http://
imagej.en.softonic.com).Total internal reflection fluorescence microscopy
ANikon Ti microscope was used for all total internal reflection fluorescence
microscopy experiments.27 The instrument was fitted with a3100 TIRF objec-
tive:NA, 1.49;Andor iXonEMCCDcamera, 405-, 491-, 561-, and 633-nm laser
lines; appropriate CFP/fluorescein isothiocyanate (FITC)/Cy3/Cy5 emission
filters; SRIC cube (IRM); a programmable mechanized stage; and infrared
autofocus (PerfectFocus,Nikon,Melville,NY).CulturedTcellswere incubated
in OK-DMEMmedium without IL-2 for 2 hours, washed, and resuspended at a
density of 107 cells/mL in Hepes buffered saline containing 1% human serum
albumin, PH 7.2 equilibrated to 378C for injection into flow chambers.Statistics
Mann-WhitneyU tests were applied for testing differences between groups
(GraphPad Prism 5 for MacOS X; GraphPad Software, San Diego, Calif).
RESULTS
Peripheral blood lymphopenia, lymphoid
hyperplasia, and autoimmunity in patients with
PHTS
In a group of 79 patients with pathogenic germline heterozy-
gous mutations in PTEN (Fig 1, A), 43% present with autoimmu-
nity, lymphoid hyperplasia, or both (autoimmunity in 27% and
lymphoid hyperplasia in 24% of patients; Fig 1, B, and see
Table E1). Susceptibility to infection was not detected (data not
shown). Peripheral total blood leukocyte counts were normal in
patients with PHTS. However, we observed in all age groups a
significant reduction in peripheral lymphocyte numbers
compared with those in control subjects (Fig 1, C, and see Fig
E1 in this article’s Online Repository at www.jacionline.org).
We then characterized blood lymphocyte subsets using FACS
(Fig 1,D andE, and see Fig E2 in this article’s Online Repository at
www.jacionline.org). There was a significant accumulation ofpatients. Colored symbols represent patients who pre
both. B, Immunologic conditions in the PHTS patient c
patients with PHTS (n5 32) and blood donor control su
boxes mark the normal range. Statistical differences w
Numbers of CD191, CD51, CD101 immature, and Ig
CD31 T cells, percentages of CD41 and CD81 T cells amCD51, CD101, and IgMhighCD38high transitional B cells (Fig 1,
D) and a significant reduction in CD41 cell numbers, resulting in
an alteration in the CD41/CD81 cell ratio (Fig 1, E, and see
Fig E2). Patients with PHTS have largely normal naive, central,
and effector memory T (Tmem) cell numbers, as well as natural
killer (NK) or NKT-cell numbers (see Figs E2, C and D, and E3
in this article’s Online Repository at www.jacionline.org). In
contrast to CD101/CD201 germinal center B cells,11 proliferation
rates in the T-cell areas of mucosa-associated lymphoid tissue
(MALT)were similar between patientswith PHTS and control sub-
jects, and the apoptosis rate of CD31 T lymphocytes in situ was
comparatively low (see Fig E4, A and B, in this article’s Online Re-
pository atwww.jacionline.org). To assess apoptosis ofT cells from
patients with PHTS in vitro, we investigated FAS ligand (CD95L)–
induced or IL-2 deprivation–induced apoptosis of T-cell blasts (see
Fig E4,C andD). No significant changes in the apoptosis rate of T-
cell blasts were detected. These findings suggest that heterozygous
pathogenic PTEN mutations have substantial effects on B-cell dif-
ferentiation and CD41 T cell numbers, but surprisingly little effect
on overall T-cell development, proliferation, and apoptosis.Normal frequency but increased proliferation of
FOXP31 T cells in situ
Increased PI3K signaling has been shown to suppress Treg cell
differentiation and function,14,17,28 in part through inhibitory ef-
fects on Foxo1 and Foxo3a.19,21,22 Therefore we investigated
the frequency of FOXP31 Treg cells, as well as FOXP3 expres-
sion levels, in patients with defects in PTEN. Although absolute
Treg cell numbers are lower in patients with PHTS, because of
the CD4 lymphopenia, similar frequencies of Treg cells were
found in peripheral blood, as well as in MALT, in patients with
PHTS compared with control subjects (Fig 2, A and B). Similar
to studies in mice,4 frequencies of Ki-671FOXP31 proliferating
cells within the lymphoid tissues of patients with PHTS were
increased (Fig 2, C).
We next measured markers of Treg cell function and suppres-
sive activity. We show that FOXP31 Treg cells of patients with
PHTS express normal levels of Helios and CTLA-4 (Fig 3,
A-C). Because murine FOXP3crePtenfl/fl Treg cells show
decreased CD25 expression,5 we compared CD25 expression of
FOXP31 Treg cells and found that human Treg cells with hetero-
zygous loss of PTEN remain phenotypically normal (Fig 3, D).
Taken together, these data suggest that PTEN deficiency
reduces FOXP31Treg cell blood numbers and affects their prolif-
eration in situ but has no effect on their phenotype.Negative control of PI3K activity downstream of
TCR activation in Treg cells
We next investigated TCR- and IL-2–induced activation of the
PI3K/AKT pathway in FACS-sorted Treg cells and CD41 Tmem
cells from healthy donors using Phosflow analysis. We foundsent with autoimmunity, lymphoid hyperplasia, or
ohort. C, Peripheral blood leukocyte counts of adult
bjects (n5 216). Each dot represents 1 patient. Gray
ere analyzed by using the Mann-Whitney test. D,
MhighCD38high transitional B cells. E, Numbers of
ong CD31 T cells, and CD41/CD81 T-cell ratio.
FIG 2. Treg cells in patients with PHTS. A, Absolute counts and frequencies of Treg cells in blood from pa-
tients with PHTS or control subjects. B, Percentages of FOXP31 cells among CD31 cells were analyzed in
MALT from control subjects and patients. Representative staining of tissue sections from patients with
PHTS is shown. C, FOXP3 and Ki-67 expression in MALT. Percentages of Ki-671 proliferating FOXP31
Treg cells were analyzed in control and patient samples. Arrows mark Ki-671FOXP31 Treg cells. Scale
bars in all images represent 50 mm.Dapi, 49, 69-Diamidino-2-phenylindole;GC, location of a germinal center.
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cells compared with Tmem cells, which is consistent with the
importance of sustained negative regulation of PI3K signaling
for Treg cell function (Fig 4, A). By contrast, Treg cells had
heightened signal transducer and activator of transcription 5 phos-
phorylation in IL-2–stimulated Treg cells compared with Tmem
cells, which is consistent with higher levels of CD25 expression
in Treg cells.
All CD41 T-cell populations, including naive and Tmem cells,
as well as Treg cells, expressed PTEN under steady-state condi-
tions. After TCR and IL-2 stimulation, Treg cells had substan-
tially upregulated PTEN levels, whereas FOXP32 T cells did
not (Fig 4, B and C).To investigate PTEN/AKT/mTOR complex 1 (mTORC1)
signaling in patients with PHTS, we analyzed the frequency of
FOXP31 cells with S6 ribosomal protein phosphorylation in situ.
There was a similar frequency of S6-phosphorylated FOXP31
cells in control subjects and patients with PHTS (Fig 4, D and
E), indicating that despite the PTEN insufficiency/dysfunction,
the signaling pathway downstream of mTORC1 is not
hyperactivated.
It is possible that heterozygous loss of PTEN could be
compensated by increased expression of the functional allele.
We examined PTEN levels in CD31 cells from a patient with a
heterozygous PTEN microdeletion, allowing the mutated and
wild-type copies to be distinguished by a C-terminal anti-PTEN
FIG 3. Phenotype of Treg cells in patients with PHTS. A, CD31CD41FOXP31CD251CD1272 cells (Treg cells)
were compared with FOXP32CD252CD1271 (naive and central Tmem cells) and FOXP32CD252CD1272 cells
(effector T cells). B, Expression levels of Helios are shown as a histogram and quantified in Treg cells. C,
Expression levels of CTLA-4 are shown as a histogram and quantified in Treg cells. D,
CD31CD41FOXP31CD1272 (Treg) cells were compared with FOXP32CD1271 (naive and central Tmem) and
FOXP32CD1272 (effector T cells) cells. CD25 expression in CD41FOXP31 Treg cells is shown as a histogram
and quantified in Treg cells. No statistical differences were detected by using the Mann-Whitney U test.
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FIG 4. PTEN activity and PI3K signaling in natural Treg cells. A, FACS-sorted Treg cells (CD41CD25highC-
D127low) and Tmem cells (CD41CD45RO1CD127highCD25low) were left unstimulated or subjected to anti-
CD3/CD28 and IL-2 stimulation for 10 minutes. Cellular levels of pAKT, pS6, and phosphorylated signal
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CHEN ET AL 9antibody (Fig 4, F). Heterozygous loss of PTEN resulted
in approximately half the cellular level of PTEN protein
(Fig 4, G).
Collectively, these observations support the paradigm that
PI3K activity in Treg cells is tightly controlled, but surprisingly,
heterozygous loss of PTEN does not increase PI3K signaling
downstream of PTEN nor does it selectively reduce FOXP31
T-cell numbers or impair their phenotype.Functional significance of PHLPP in Treg cells
We hypothesized that the insufficiency in PTEN might be
functionally compensated by other phosphatases. We performed
gene expression analysis of phosphatases targeting phosphatidy-
linositol (3,4,5)-trisphosphate or pAKT in Treg cells compared
with PBMCs, CD41 T cells, and B cells. Indeed, not only PTEN
but also PHLPP1, Src homology domain 2–containing inositol
phosphatase (SHIP) 1, and PHLPP2 were expressed at relatively
high levels in FOXP3-expressing cells, and PHLPP expression in
FOXP31 cells was confirmed by means of immunohistochem-
istry (see Fig E5 in this article’s Online Repository at www.
jacionline.org).
To interrogate the functional role of those phosphatases, we
performed an in vitro induced regulatory T (iTreg) cell inducer
assay by using increasing numbers of T-cell activator beads (see
Fig E6, A and B, in this article’s Online Repository at www.
jacionline.org). The strongest induction of FOXP31 iTreg cells
that suppressed proliferation of naive CD41 T cells in vitro was
achieved by using a high ratio of beads to cells (see Fig E6, B
and C). We investigated the effects of various small-molecule in-
hibitors against phosphatases regulating the PI3K pathway (see
Fig E6,D). The induction of iTreg cells was significantly reduced
by inhibition of PHLPP1/2 and simultaneous inhibition of
PHLPP1/2 and PTEN but not by PTEN inhibition alone or by in-
hibition of SHIP1, SHIP2, or protein phosphatase 2A (PP2A; Fig
5, A-C). Therefore PHLPP plays a key role in the conversion of
naive CD41 T cells to iTreg cells. We confirmed the target activ-
ities of the PTEN and PHLPP inhibitors by measuring pAKTand
pS6 levels in HEK293T cells (see Fig E7 in this article’s Online
Repository at www.jacionline.org). The effects of PHLPP inhibi-
tion on iTreg cell generation was highest with the plate-bound
TCR stimulus (Fig 5, B). Collectively, our data suggest that
PHLPP is expressed in Treg cells in situ and ex vivo and that
PHLPP activity is essential for the induction of iTreg cells.transducer and activator of transcription 5 (pSTAT5)
analyzed by using Phosflow. B and C, PBMCs from hea
with anti-CD3 and anti-CD28 T-cell activator beads in th
regulatory and FOXP31 Treg cell populations among to
changes in PTEN protein levels after TCR and IL-2 recep
FOXP31 cells, as well as phosphorylation of the S6 ribos
E, Percentage of pS61 expressing cells among FOXP31
determined by using immunohistochemical staining.
represent means. Differences were analyzed by usin
dependent probe amplification copy number analysis
exon 9 and a 39 untranslated region (UTR) of PTEN. Pr
a patient with PHTS with the microdeletion (del E2-9)
CD31 T cells from a control donor or a patient with PH
by using FACS with an mAb that recognizes the C-ter
of the nonmutated copy of PTEN protein. PTEN levels
CD28 and IL-2 stimulation for 24 hours.Given the importance of PI3K/mTOR in mitochondrial
metabolism, we next examined the decrease in mitochondrial
membrane potential in blood-derived Treg cells treated with
increasing concentrations of the PTEN inhibitor either alone or in
combination with the PHLPP inhibitor (Fig 5,D andE).We found
that simultaneous blockade of both phosphatases resulted in
significantly decreased membrane potential compared with
blocking PHLPP or PTEN alone. Similar to intermediate
PTEN inhibitor concentrations, the TMRE assay performed on
patients’ Treg cells with haploinsufficient PTEN showed normal
mitochondrial membrane potential (Fig 5, F), suggesting func-
tional compensation for PTEN. Further studies are needed to
clarify whether the loss-of-function PHLPP2 polymorphism
p.L1016S is associated with autoimmunity in patients with
PHTS (see Fig E8 in this article’s Online Repository at www.
jacionline.org).PTEN, PHLPP, and NHERF1 in Treg cells
We next investigated interaction partners of PTEN and PHLPP
using the STRING database (http://string-db.org). This indicated
that the phosphatases PTEN and PHLPP can form shared protein-
protein interaction networks through scaffold proteins, including
NHERF1 (encoded by SLC9A3R1), NHERF2 (encoded by
SLC9A3R2), and scaffold protein discs, large homolog 1
(DLG1; see Fig E9, A, in this article’s Online Repository at
www.jacionline.org).
To validate this in silico prediction, we performed mRNA gene
expression analysis. Treg cells showed a 3-fold higher level of
NHERF1 mRNA compared with PBMCs or whole CD41
T cells, CD41CD45RO1 Tmem cells, and B cells (see Fig E9,
B). The membrane-cytoskeleton linkers ezrin and moesin and
DLG1 all displayed relatively high expression in Treg cells.
NHERF1 is differentially expressed among lymphocytes in the
T-cell area of human appendix sections, and FOXP31 cells
express medium to high levels of NHERF1 protein in situ (see
Fig E9, C).
NHERF1 is a candidate for mediating active assembly of PTEN
and PHLPP. It contains PDZ domains that can link PTEN and
PHLPP phosphatases through their PDZ-binding motifs.29-31 We
confirmed physical association between NHERF1, PTEN, and
PHLPP by means of immunoprecipitation of PTEN in the NIH/
3T3 cell line, which expresses all 3 proteins constitutively (see
Fig E10).in each cell type with or without stimulation were
lthy donors were rested or stimulated for 24 hours
e presence of IL-2. PTEN expression in FOXP32 non-
tal PBMCs was measured by using FACS to detect
tor stimulation. D, MALT sections were stained for
omal protein (p[Ser235/236]S6). Scale bar5 50 mm.
cells in patients with PHTS versus control subjects
Symbols represent individual patients, and lines
g the Mann-Whitney U test. F, Multiplex ligation-
revealing a microdeletion spanning from exon 2 to
otein representation of a wild-type (wt) subject and
are shown for comparison. G, PTEN expression in
TS (del E2-9, PTEN microdeletion) was determined
minal region of PTEN, allowing selective detection
were measured in cells with or without anti-CD3/
FIG 5. Functional complementation between PTEN and PHLPP in Treg cells. A, Effects of small-molecule in-
hibitors of PTEN, PHLPP, SHIP1, SHIP2, and PP2A on iTreg cell differentiation in vitro. CD41 naive human
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CHEN ET AL 11Recruitment of PTEN, PHLPP, and NHERF1 to the
immunologic synapse on TCR stimulation in Treg
cells
Through their association with membrane-cytoskeleton linkers,
phosphatases can assemble into a network that allows rapid
reconfiguration of their subcellular distribution on TCR stimula-
tion. Association between phosphatases and scaffold components
in Treg cells suggests a mechanism that allows polarized phospha-
tase activity at sites where regulated PI3K signaling is required.
A likely place for such polarized phosphatase activity is the
immunologic synapse. Therefore we quantified the polarization
of PHLPP, PTEN, and NHERF1 using confocal laser-scanning
microscopy. CD41CD251Treg cells were activated by exposure to
anti-CD3– and ICAM-1–coated glass slides. Within 15 minutes,
PHLPP, PTEN, and NHERF1 accumulated toward the anti-CD3–
and ICAM-1–coated glass surface but not toward the nonactivating
ICAM-1–coated surface (Fig 6, A-C), suggesting that both phos-
phatases and NHERF1 actively accumulate at the site of the TCR
ligation–triggered cellular signaling complex.
To confirm that these molecules are being recruited to the
immune synapse, we used total internal reflection fluorescence
microscopy on supported planar lipid bilayers. Consistent with
the results from confocal imaging experiments, we observed
clustering of PTEN, NHERF1, and PHLPP in the peripheral
supramolecular activation complex within the immunologic
synapse (Fig 6, D). Our observations suggest that a dynamic
PTEN-NHERF1-PHLPP protein network is initiated after TCR
stimulation in Treg cells, allowing simultaneous recruitment of
the phosphatases to the site of TCR activation.DISCUSSION
Because PTEN controls PI3K/AKT/mTOR signaling and
patients with PHTS present with significant changes in the T-
and B-cell compartment associated with autoimmunity, colitis,
and lymphoid hyperplasia,11 we expected abnormalities in the
Treg cell compartment. Along with a CD41 T-cell lymphopenia,
FOXP31 T-cell numbers are reduced in the blood of patients with
PHTS, but we observed normal frequency of Treg cells in the
blood and colon. Treg cells have normal CTLA-4, Helios, and
CD25 expression, as well as normal mitochondrial polarization,
together indicating a largely functional Treg cell phenotype.
This might appear contradictory to recent studies demon-
strating that homozygous loss of Pten in a Foxp3CrePtenfl/flmurine
model leads to reduced suppressive activity of Treg cells and in-
duction of autoimmunity.5,6 Murine Treg cells deficient in Pten
display downregulation of CD25 and Foxp3 expression, impairedT cells were cultured for 4 days in the presence of vario
A dimethyl sulfoxide concentration-matched control w
each condition at the end of the 4-day culture are sho
formed in quadruplicate. Results are representative o
was performed at medium TCR stimulation signal stre
signal strength on the extent of blockade of iTreg cell g
sentative FACS plots demonstrating the effects of the P
tion. D and E, Mitochondrial depolarization in blood
Mitochondrial membrane potential was measured by
Treg cells treated with a PTEN inhibitor at 0.4, 2 (IC50),
inhibitor (used at an IC50 of 70 mmol/L). Dimethyl su
Data are pooled from 8 healthy donors. Each point repr
by using the Mann-Whitney U test. F, Mitochondrial de
PHTS and control subjects. TMRE fluorescence in Tregmitochondrial fitness, and loss of Treg cell lineage stability.5,6
The differences in immune phenotype between mice with Treg
cell–specific Pten homozygous deletion and patients with PHTS
can be explained by the gene-dose effect of PTEN expression
and the complementary phosphatase activity of PHLPP that we
describe in this study.
PHLPP has been shown previously to be upregulated in murine
and human Treg cells compared with conventional T cells and is
indispensable for murine Treg cell suppressive function, as well
as iTreg cell generation.32 Murine PHLPP1-deficient Treg cells
are unable to protect against colitis induced by naive CD41
T-cell transfer.32 Our data show that PHLPP acts as a crucial
negative regulator of PI3K signaling in human subjects, as
demonstrated by deleterious effects of PHLPP blockade on iTreg
cell induction and natural Treg cell mitochondrial fitness. Larger
patient groups are required to determine whether a loss-
of-function polymorphism in PHLPP2 might contribute to the
susceptibility of autoimmunity. PTEN and PHLPP both prevent
excessive accumulation of pAKT, which explains our observation
that despite PTEN haploinsufficiency, we found normal FOXP31
Treg cell frequencies and no increase in expression their phos-
phorylated ribosomal protein S6 (pS6), a downstream marker of
mTORC1 activation. PTEN and PHLPP have both been shown
to display cytosolic and mitochondrial localization, in which
PTEN regulates mitochondrial function and metabolism and
PHLPP regulates mitochondrial Akt activity.33,34 Therefore
PTEN and PHLLP canmodulate mitochondrial functions through
regulation of the PI3K/mTOR axis but might have additional non-
canonical, mTOR-independent effects on mitochondrial fitness
through their protein phosphatase activities.
T- and B-cell dysfunctions have been described in patients with
activating mutations in PI3Kp85a (encoded by PIK3R1)35 and
PI3Kp110d (encoded by PIK3CD).36 There are striking similar-
ities in the clinical phenotype of patients with gain-of-function
PI3K activity and patients with loss-of-function PTEN defects,
such as immune dysregulation, lymphopenia, increased transi-
tional B-cell counts, and reduced CD4/CD8 ratio. The cause of
immune dysregulation in patients with PHTS is likely due to a
combination of factors, including differential B-cell apoptosis,
proliferation, and differentiation11; lymphopenia as a risk factor
for autoimmunity37; potential abnormalities in the follicular
T-cell compartment, as demonstrated in PTEN-deleted T cells
in mice38; or alterations in Treg cells during inflammation or
cellular stress. A relevant immunodeficiency component is excep-
tionally rare in patients with PTEN haploinsufficiency but more
prevalent in patients with gain-of-function PI3K mutations, again
indicating a gene-dose effect.us inhibitors under iTreg cell–inducing conditions.
as used. Total numbers of CD41FOXP31 cells for
wn. Bars represent means 6 SDs for a culture per-
f 3 independent experiments. iTreg cell induction
ngth (1 bead: 2 cells). B, Effects of TCR stimulation
eneration by inhibitors of PTEN or PHLPP. C, Repre-
TEN and PHLPP inhibitors on iTreg cell differentia-
Treg cells after PTEN and/or PHLPP inhibition.
using the TMRE assay in CD41CD25highCD127low
or 4 mmol/L alone or in combination with a PHLPP
lfoxide concentrations are equal in all conditions.
esents 1 donor, and differences have been assessed
polarization in blood Treg cells from patients with
cells is shown as a histogram and quantified.
FIG 6. Phosphatase andNHERF1 assembly at the immunologic synapse.A-C, Laser-scanningmicroscopy of
CD41CD251 T cells stimulated on CD3- and ICAM-1–coated glass slides. Time-dependent accumulation of
PHLLP, PTEN, and NHERF1 after anti-CD3–mediated TCR activation was assessed by measuring protein
accumulation in the planar layer adjacent to the glass slide. Exposure to ICAM-1 without TCR engagement
served as a negative control. Dots represent individual cells analyzed. D, PTEN, NHERF1, and PHLLP subcel-
lular localization in relation to the central supramolecular activation complex (indicated by CD3 staining)
and peripheral supramolecular activation complex (indicated by ICAM-1 staining) was analyzed by using
TIRF microscopy. Differences were analyzed by using the Mann-Whitney U test.
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Treg cells after immune cell–expressed semaphorin-4a ligation
with the Treg cell receptor neuropilin 1 was recently described.39
Deletion of PTEN in Foxp3-Cre Ptenfl/fl Treg cells leads to
increased Akt phosphorylation at TCR microclusters on
semaphorin-4a/neuropilin 1 interaction, indicating the impor-
tance of localized phosphatase action at the immunologic syn-
apse. Our finding that PTEN and PHLPP accumulate at theimmunologic synapse on TCR ligation suggests an active phos-
phatase network. The immunologic synapse comprises the central
supramolecular activation complex characterized by accumula-
tion of extracellular microvesicles and the peripheral supramolec-
ular activation complex (characterized by ICAM-1 and
lymphocyte function-associated antigen 1 accumulation inter-
spersed with actively signaling TCR microclusters).27 Although
large transmembrane phosphatases, such as CD45, are excluded
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PHLPP are found within the microclusters in Treg cells, where
they might regulate AKT phosphorylation status at the immuno-
logic synapse in a coordinated fashion.
A dysfunctional phosphatase network comprising PTEN and
PHLPP, as well as the scaffold protein NHERF1, has been
recently described in glioblastoma cells.30 NHERF1 is known as a
mediator of polarizing cell activity in epithelial cells. We show
that NHERF1 is expressed in human Treg cells, where TCR stim-
ulation leads to accumulation at the immunologic synapse along-
side PTEN and PHLPP. Similarly, a further scaffold protein in this
phosphatase network, DLG (encoded by DLG1), has been
recently described in Treg cells.42
In summary, our data suggest that PTEN haploinsufficiency in
patients leads to immune dysregulation but permits a normal Treg
cell phenotype in vivo because of the compensatory phosphatase
activity of PHLPP. A network supported by the scaffold proteins
allows active recruitment of the phosphatases to the plasma mem-
brane at the site of TCR stimulation, thus providing a failsafe
mechanism in this critical pathway through multiple layers of co-
ordinated negative regulation.
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excellent technical assistance. We thank Arian Laurence for comments on the
manuscript. PHLPP inhibitor was kindly provided by Alexandra Newton and
the US National Cancer Institute. The study was supported by the Oxford GI
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Key messages
d PTEN haploinsufficiency leads to human immune
dysfunction, but normal frequency and phenotype of
CD41FOXP31 Treg cells are found.
d PTEN and PHLPP form a phosphatase network to main-
tain checkpoint control at the immunologic synapse in hu-
man Treg cells.
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Immunohistochemistry and fluorescence
microscopy
The following antibodieswere used: anti-CD3 (polyclonal;Dako,Glostrup,
Denmark), anti-CD10 (clone 56C6; Leica, Wetzlar, Germany), anti-CD20
(clone L26; Dako), anti–Ki-67 (cloneMib-1 or anti–Ki-67–FITC cloneMib-1
FITC labeled; Dako), anti-FOXP3 (clone 236A/E7; Abcam), anti–p(Ser235/
236)-S6 (clone D57.2.2E; Cell Signaling), anti-NHERF1 (NB300-536; Novus
Biologicals, Littleton, Colo), and anti-PHLPP (IHC-00382; Bethyl Labora-
tories, Montgomery, Tex). POD-labeled anti-mouse IgG (polyclonal donkey),
anti-rabbit IgG (donkey polyclonal), and anti-FITC (clone 1F8-1E4; all from
Jackson ImmunoResearch) were used to detect primary antibodies. 49, 69-
Diamidino-2-phenylindole staining was performed to visualize nuclei.
Flow cytometry
After erythrocyte lysis (FACS Lysing Solution; BD), patient and control
samples were washed with PBS, stained, and fixed with 1% formaldehyde
solution. Flow cytometry was performed on a FACSCalibur (BD) by using
CellQuest Pro Software (BD), as well as a FACSCanto II with BD FACSDiva
software (version 6.1.3) and FACSCalibur with CellQuest Pro software
(version 4.0.2), respectively. The following antibodies were used: anti-CD3
(clone SK7 or clone UCHT1, peridinin-chlorophyll-protein complex [PerCP]
or Pacific Blue; BD), anti-CD4 (clone 13B8.2, allophycocyanin [APC] or
phycoerythrin [PE]-cyanin 5.1; Immunotec, Vaudreuil-Dorion, Quebec, Can-
ada), anti-CD8 (clone SK1, PerCP; BD), anti-CD25 (clone 2A3, FITC; BD),
anti-CD45 (clone 2D1, APC-H7 or APC-Cy7; BD), anti-CD45RO (UCHL1,
PerCP-Cy5.5; BD), anti-CD56 (clone NCAM16.2, PE-Cy7; BD), anti-CD62L
(clone GREG-56, APC-Cy7; Biozol, Eching, Germany), anti-CD127 (clone
R34.34, PE; Immunotec), anti-CCR7 (clone 3D12, PE-Cy7; BD), anti-FOXP3
(clone PCH101, PE; NatuTec, Frankfurt, Germany), and anti-PTEN (clone
Y184; Epitomics). Isotype-matched mAbs served as controls. Treg cells in
peripheral blood were detected by means of intracellular staining of FOXP3
according to the manufacturer’s instructions (FOXP3 Staining Set; NatuTec)
and/or expression of the surface molecule CD127 in combination with CD25
and CD4.
Characterizing cellular levels of PTEN
PBMCs were rested for 24 hours (unstimulated) or stimulated with
Dynabeads Human T-Activator CD3/CD28 (Life Technologies, Grand Island,
NY; 1 bead: 2 cells) and IL-2 (100 IU/mL). Cells were then stained with CD3,
CD4, CD25, and CD45RA and fixed and permeabilized with Cytofix/
Cytoperm (BD Biosciences), followed by anti-PTEN staining (clone Y184;
Epitomics) in BD Perm/Wash buffer, washed, and subjected to another
fixation/permeabilization procedure by using the Foxp3/Transcription Factor
Staining Buffer Set (eBioscience), followed by FOXP3 staining. Cells from
each source were rested for 24 hours in 10% FCS RPMI or stimulated with
beads (bead/cell ratio, 1:1) and IL-2 (100 IU/mL) before FACS analysis to
compare PTEN levels in T cells from a patient with PHTS versus a healthy
control subject.
In vitro Treg cell inducer assays
Naive human T cells were cultured for 5 days with TCR stimulation (T-cell
activator beads), 50 IU/mL IL-2, 5 ng/mL TGF-b, and 50 mmol/L b-
mercaptoethanol in RPMI containing 5% FCS and 25 mmol/L HEPES.
Biochemical inhibition of the phosphatases PTEN, PHLPP, SHIP1, and PP2A
was achieved by using inhibitors with specific activity against PTEN (2mmol/
L, SF1670; Cellagentech, SanDiego, Calif), PHLPP (50mmol/L, 1,3-[[4-(2,4-
diamino-5-methylphenyl)-diazenylphenyl]hydrazinylidene]-6-oxocyclohexa-
1,4-diene-1-carboxy-lic acid [US NCI, NCS 45586]), SHIP1 (10 mmol/L,
3a-aminocholestane;MerckMillipore, Billerica, Mass), SHIP2 (0.57mmol/L,
AS1938909; Merck Millipore), and PP2A (0.1 nmol/L Okadaic acid; Cell
Signaling), respectively. Inhibitors were used at their respective IC50 concen-
trations, except for the PHLPP inhibitor, which was used at 50 mmol/L (IC50,
70 mmol/L) because of the low solubility of the compound. Inhibitors were
added to culture medium 2 hours after setting up iTreg cell cultures andreplenished after 48 hours. Cells were analyzed by using FACS for expression
of CD4, CD25, and FOXP3. Concentration-matched dimethyl sulfoxide for the
highest solvent concentration was used as a control.
Quantitative RT-PCR
Total PBMCs, total CD41 T cells, CD41CD251CD127low Treg cells,
CD41CD45ROhigh Tmem cells, and CD191 B cells were FACS sorted, and
total cellular RNAwas extracted with an RNeasy RNA extraction kit (Qiagen,
Hilden, Germany). Subsequently, RNAwas reverse transcribed into cDNA by
using the Quantiscript Reverse Transcription kit (Qiagen). Quantitative PCR
was performed with gene-specific primers (QuantiTect Primer Assays, Qia-
gen) against human PTEN, SHIP1, PHLPP1, PHLPP2, NHERF1, ezrin,
DLG1, moesin, and FOXP3 by using the Maxima SYBR Green qPCRMaster
Mix (Thermo Scientific). Gene levels were normalized to 18S rRNA.
Terminal deoxynucleotidyl transferase dUTP nick
end-labeling
Apoptosiswas detected by using theApopTag Peroxidase In SituApoptosis
Detection Kit (Chemicon, Temecula, Calif), as previously described.E1 In
brief, staining for CD3, CD10, or CD20 was performed by using tyramide
amplification, which created covalent linkage between fluorescent dyes and
tissue components. The sections were subsequently treated with proteinase
K. After blockade of the remaining peroxidase activity, the terminal deoxynu-
cleotidyl transferase dUTP nick end-labeling assay was performed with anti-
digoxigenin–POD and subsequent tyramide fluorescence probe amplification.
Counterstaining was performed with 49, 69-diamidino-2-phenylindole.
T-cell proliferation suppression assay
iTreg cells were labeled with the CellTrace Violet Cell Proliferation Kit
(Life Technologies) and cocultured with carboxyfluorescein succinimidyl
ester–labeled allogeneic CD41 naive (responder) T cells at a 1:1 ratio. Cells
were cultured for 4 days before being subjected to FACS analysis to determine
cell proliferation based on carboxyfluorescein succinimidyl ester dilution. The
proliferation of responder T cells without the presence of iTreg cells was used
as a control.
In vitro apoptosis assay
PBMCswere stimulated with PHA (1.25mg/mL) and IL-2 (100 IU/mL) for
3 to 5 days and for another 2 to 5 days with IL-2 alone (100 IU/mL). T-cell
blasts were subsequently stimulated with increasing concentrations of
recombinant human CD95L and enhancer (Alexis Biochemicals, Lausen,
Switzerland) for 24 hours. After staining with Annexin V and propidium
iodide, apoptosis was quantified by using FACS. Titration curves and control
values from healthy donors served as control values.
Immunoblotting and immunoprecipitation
NIH/3T3 cells were lysed in protein lysis buffer. For immunoprecipitation,
protein lysates were incubated with goat polyclonal anti-human PTEN
antibody (N-19; Santa Cruz Biotechnology, Dallas, Tex) and protein G–
Sepharose (GE Healthcare Life Sciences, Fairfield, Conn) overnight at 48C.
Immunoprecipitates were washed in lysis buffer and then denatured in an
equal volume of 23 SDS-PAGE sample buffer and subjected to electropho-
resis for immunoblotting. ForWestern blotting, whole-cell lysates weremixed
with the same volume of 23 SDS-PAGE sample buffer and subjected to
electrophoresis for immunoblotting. The primary antibodies used for immu-
noblotting were rabbit polyclonal anti-human PHLPP (IHC-00382; Bethyl
Laboratories), rabbit polyclonal anti-human NHERF1 (EBP50; Novus Bi-
ologicals), and goat polyclonal anti-human PTEN (N-19; Santa Cruz
Biotechnology). Western blotting was carried out according to the standard
protocol.
PTEN mutation and PHLPP2 polymorphism analysis
Genomic DNA was extracted from peripheral blood leukocytes by using
standard protocols. PTENmutation analysis with Sanger sequencing and copy
homeostasis in patients with PTEN hamartoma tumor syndrome. Gastroenter-
ology 2012;142:1093-6.e6.
E2. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial
PTEN expression throughout the human menstrual cycle. J Clin Endocrinol
Metab 2000;85:2334-8.
E3. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, et al. Germline
PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba
syndrome result in aberrant PTEN protein and dysregulation of the
phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003;73:404-11.
E4. Reifenberger J, Rauch L, Beckmann MW, Megahed M, Ruzicka T, Reifenberger
G. Cowden’s disease: clinical and molecular genetic findings in a patient with a
novel PTEN germline mutation. Br J Dermatol 2003;148:1040-6.
E5. Teresi RE, Zbuk KM, Pezzolesi MG, Waite KA, Eng C. Cowden syndrome-
affected patients with PTEN promoter mutations demonstrate abnormal protein
translation. Am J Hum Genet 2007;81:756-67.
E6. Montgomery J, Wittwer CT, Palais R, Zhou L. Simultaneous mutation scanning
and genotyping by high-resolution DNA melting analysis. Nat Protoc 2007;2:
59-66.
E7. Erali M, Wittwer CT. High resolution melting analysis for gene scanning.
Methods 2010;50:250-61.
E8. Garritano S, Gemignani F, Voegele C, Nguyen-Dumont T, Le Calvez-Kelm F, De
Silva D, et al. Determining the effectiveness of high resolution melting analysis
for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet 2009;
10:5.
E9. Brognard J, Niederst M, Reyes G, Warfel N, Newton AC. Common polymor-
phism in the phosphatase PHLPP2 results in reduced regulation of Akt and pro-
tein kinase C. J Biol Chem 2009;284:15215-23.
E10. Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, et al. A clinical
scoring system for selection of patients for PTEN mutation testing is proposed
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performed by using a combination of different standard methods.E1-E5 The
PHLPP2 L1016S polymorphism (rs61733127) was analyzed by using Light-
Scanner High Resolution DNA Melting (HRM) analysis. Primers and probe
were designed to have a melting temperature of between 598C and 658C
with LightScanner Primer Design software (Idaho Technology, Salt Lake
City, Utah). Oligonucleotide sequences were as follows: PHLPP2,
GCTGTCAATGCTGTACGTC (forward); PHLPP2, ATATTCAAATAAAC-
TACCATCGCCC (reverse); and TGTGCACATCAGCGCAGAG-phosphate
(probe). PCR reactionswere performed at an optimized annealing temperature
of 62.58C in a total volume of 10 mL containing 4 mL of 2.53 LightScanner
Mastermix, 1mL of genomic DNA (25 ng/mL), 1mL of primer mix (final con-
centration: 0.1 mmol/L of forward primer, 0.5 mmol/L of reverse primer, and
0.5mmol/L of the probe), and 4mL of LightScanner Reagent GradeWater. Re-
action mixtures were overlaid with 20 mL of mineral oil to avoid evaporative
losses, ensuring melting curve uniformity. HRM curves were analyzed by us-
ing the LightScanner software (Idaho Technology), according to the protocols
described previously.E6 The ‘‘unlabeled probe’’ module in the ‘‘genotyping’’
mode of the software was used for HRM analyses involving negative filter,
normalization, and grouping. Genotyping by using HRM was based on probe
melting temperature, which was obtained from negative derivative melting
curve plots. These analytic methods have been used previously for single
nucleotide polymorphism genotyping.E7,E8 Samples showing abnormal
melting curves were purified and sent for Sanger sequencing for validation.
Sequences were analyzed by using Mutation Surveyor DNAVariant Analysis
Software (SoftGenetics, State College, Pa).REFERENCES
E1. Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Auto-
immunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell
on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011;
88:42-56.
E11. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastroin-
testinal polyps and colorectal adenocarcinomas in a prospective series of PTEN
mutation carriers. Gastroenterology 2010;139:1927-33.
FIG E1. Leukocyte and lymphocyte counts in peripheral blood of patients
with PHTS, with age indicated. A, Leukocyte counts. B, Lymphocyte counts.
Lines represent the upper and lower normal reference.
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FIG E2. Lymphocyte subsets of patients with PHTS (proportions). A, Frequencies of CD191, CD51, CD101
immature, and IgMhighCD38high transitional B cells. B, Frequencies of CD31 T cells and percentages of
CD41 and CD81 T cells among CD31 T cells. C, Frequencies of HLA-DR1 activated T cells and CD45RO2 naive
T cells, CD45RO1CCR71 central memory CD41 T cells, and CD45RO1CCR72 effector memory CD41 T cells.
D, Frequencies of CD45RO1CCR71 central memory CD81 T cells and CD45RO1CCR7- effector memory CD81
T cells. E, Frequencies of CD161CD561 NK cells and CD31CD561 NKT cells. Each dot represents 1 patient.
Themean is presented by the red line. Statistical differences were analyzed by using theMann-Whitney test.
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FIG E3. FACS analysis of T-cell subsets, NK cells, and NKT cells in peripheral blood of patients with PHTS
(absolute numbers). A, Levels of HLA-DR1 activated T cells and CD45RO2 naive T cells, CD45RO1CCR71
central memory CD41 T cells, and CD45RO1CCR72 effector memory CD41 T cells. B, Levels of
CD45RO1CCR71 central memory CD81 T cells and CD45RO1CCR72 effector memory CD81 T cells. C, Levels
of CD161CD561 NK cells and CD31CD561 NKT cells. Each dot represents 1 patient. The mean is presented
by the red line. Statistical differences were analyzed by using the Mann-Whitney test.
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FIG E4. Proliferation and apoptosis in lymphocytes from patients with PHTS. A, Gut tissue sections from
patients with PHTS or control subjects were stained for Ki-67. Cell proliferation was analyzed within the
T-cell areas. E, Epithelium. B, CD3, CD20, and CD10 costaining with terminal deoxynucleotidyl transferase
dUTP nick end-labeling (TUNEL) for apoptosis detection in control appendix sections. The graph demon-
strates the percentage of TUNEL1 cells that are CD31, CD201, or CD101. Differences were analyzed by using
the Mann-Whitney test. Scale bars 5 50 mm. Symbols represent individual patients. C and D, In vitro
apoptosis assays. Apoptosis was induced in PHA-activated T-cell blasts by means of CD95L (FasL) stimula-
tion (Fig E4, C) or IL-2 deprivation (Fig E4, D). Percentages of surviving cells are shown for 1 patient with
PHTS (p.R130Q) and 2 healthy control subjects. Similar results have been obtained by using analysis of 6
further patients with PHTS with different mutations in an independent experiment (data not shown).
Dapi, 49, 69-Diamidino-2-phenylindole.
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FIG E5. Phosphatases in PBMCs and blood-derived lymphocyte subsets. A and B, mRNA gene
expression analysis in PBMCs compared with FACS-sorted B cells, whole CD41 T cells, Tmem cells, and
CD41CD251/high Treg cells. Comparative gene expression analysis of FOXP3 (Fig E5, A) and different phos-
phatases (PTEN, SHIP1, PHLPP1, and PHLPP2; Fig E5, B) regulating the PI3K/AKT/mTOR signaling pathway.
Values are normalized to 18S rRNA. Means and SDs are shown for triplicate values. C, Immunohistochem-
ical detection of PHLPP protein in FOXP31 cells. Images show representative PHLPP staining in FOXP31
cells in a control appendix section. DAPI, 49, 69-Diamidino-2-phenylindole.
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FIG E6. iTreg assay and blockade of iTreg generation by phosphatase-specific inhibitors. A, In vitro differ-
entiation of naive T cells into FOXP3 iTreg cells. B, Effects of TCR signal strength on FOXP3 induction. TCR
stimulation was provided by T-cell activator beads or plate-bound anti-CD3 (10 mg/mL)/soluble anti-CD28
(1 mg/mL). C, In vitro T-cell proliferation suppression assay. Carboxyfluorescein succinimidyl ester
(CFSE)–labeled naive (responder) T cells were cocultured with anti-CD3/anti-CD28 beads in the presence
and absence of iTreg cells. Responder T-cell proliferation was measured by means of CFSE dilution. Data
are representative of 2 independent experiments. D, Small-molecule inhibitors were used to block various
phosphatases (PTEN, PHLPP1/2, SHIP1, SHIP2, and PP2A) that provide negative regulation at different
points of the PI3K/AKT/mTOR signaling pathway.
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FIG E7. Effects of the small-molecule inhibitors of PHLPP and PTEN on AKT/S6 phosphorylation. A, Levels
of pAKT and pS6 in HEK293T cells with or without PHLPP inhibitor treatment. HEK293T cells were plated for
24 hours in Dulbecco modified Eagle medium supplemented with 10% FCS before serum starvation. Cells
were then incubated for 24 hours in the presence or absence of 10% FCS (starvation or no starvation, respec-
tively). Where appropriate, the PI3K inhibitor LY294002 was added to cells 6 hours after the start of serum
starvation and left on for 18 hours to further reduce baseline levels of pAKT in serum-starved cells. Before
fixation of cells for Phosflow, cells were exposed to the PHLPP inhibitor for 20 or 30 minutes. pAKT and pS6
levels were measured by using Phosflow. Data are representative of 2 independent experiments. B, Levels
of pAKT in HEK293T cells with or without PTEN inhibitor treatment. HEK293T cells were plated for 24 hours
in Dulbecco modified Eagle medium supplemented with 10% FCS before serum starvation. Cells were then
incubated for 24 hours in the presence or absence of 10% FCS (starvation or no starvation, respectively).
Before fixation of cells for Phosflow, cells were exposed to the PTEN inhibitor SF1670 for 30 minutes.
pAKT levels were measured by using Phosflow.
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FIG E8. Effect of PHLPP2 polymorphism p.L1016S in patients with pathogenic PTEN mutations. A, Sanger
sequencing of wild-type and c.3047T>C (p.L1016S) variants. B, LightScanner analysis. C, PHLPP2 genotype-
phenotype analysis. Sixty-six patients with PHTS were analyzed for the L1016S variant and autoimmune
and lymphoid hyperplasia phenotype. Potential gene-gene interaction between PTEN and PHLPP2 was
investigated by determining whether the hypomorphic polymorphism in PHLPP2 (p.L1016S) with reduced
dephosphorylation activity at the C-terminal hydrophobic motif Ser473 of AKTE9 has a detectable effect on
the immune phenotype in patients with PHTS. The p.L1016S variant is present in about one fifth of the hu-
man populationE9 and was similarly frequently detected in the PHTS cohort. Although there is no literature
to suggest that this polymorphism hasmajor relevance for the development of autoimmunity in the general
population with wild-type PTEN, we hypothesized that this polymorphism could be relevant for patients
who harbor a pathogenic PTEN mutation and would therefore likely have a different PI3K-AKT signal acti-
vation threshold. There was a nonsignificant trend toward an increased frequency of autoimmunity and no
significant difference in lymphoid hyperplasia between patients with PHTS with wild-type or L1016S vari-
ants. Our data suggest that heterozygous loss of PHLPP2 phosphatase activity has a potential effect on auto-
immunity in those patients, but despite analysis of 66 patients with PHTS, this is underpowered.
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FIG E9. Expression of scaffold proteins in Treg cells.A,Molecular interactions between PTEN and PHLPP1/2
suggest a protein network that links those phosphatases with the structural scaffold proteins NHERF1/2
and the membrane linker ezrin (EZR; String database 9.0, high-confidence setting). B, mRNA gene expres-
sion analysis in PBMCs compared with FACS-sorted B cells, whole CD41 T cells, Tmem cells, and
CD41CD251/high Treg cells. Comparative gene expression analysis of the structural proteins NHERF1,
EZR, DLG1, and moesin (MSN) is shown. Values are normalized to the 18S rRNA level in each cell popula-
tion. Means and SDs are shown for triplicate values. NHERF2 expression was not detected (data not shown).
C, Immunohistochemical detection of NHERF1 expression in FOXP31 cells. Images show representative
NHERF1 staining in the control appendix section. DAPI, 49, 69-Diamidino-2-phenylindole.
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FIG E10. Interaction of PTEN with PHLPP and NHERF1 in NIH/3T3 cells.
Immunoprecipitation of PTEN followed by Western blot analysis for PTEN,
NHERF1 and PHLPP in NIH/3T3 cells. Enrichment of PHLPP and NHERF1 in
the immunoprecipitated anti-PTEN fraction but not in control IgG precip-
itate (IB) demonstrates physical association between PTEN and NHERF1 or
PHLPP. For comparison, PTEN, PHLPP, and NHERF1 levels are shown
before (Input) and after immunoprecipitation (supernatant post IP).
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TABLE E1. Characteristics of patients with PHTS, including age, sex, clinical phenotype, genotype variation, protein variation, and
immune phenotype
Patient no. Sex Age (y) Phenotype Genotype variation Protein variation Autoimmunity Lymphoid hyperplasia
1 Male 65 CS/BRRS c.395G>A p.Gly132Asp d
2 Male 49 CS c.800delA p.Lys267ArgfsX9 d
3 Female 34 CS c.287C>G p.Pro96Arg
4 Male 7 CS c.18_19delAG p.Glu7AspfsX3
5 Female 40 CS c.1003C>T p.Arg335X d
6 Female 60 CS c.1033C>G p.Leu345Val d
7 Female 49 CS c.49C>T p.Gln17X d d
8 Female 60 CS c.697C>T p.Arg233X
9 Male 25 CS c.1-?_12121?del d
10 Female 14 CS c.1003C>T p.Arg335X
11 Male 48 CS c.388C>T p.Arg130X d d
12 Female 68 CS c.126_127insTC p.Glu43SerfsX12
13 Female 59 CS c.1-?_12121?del d
14 Female 50 CS c.235G>A p.Ala79Thr d
15 Male 5 CS c.737C>T p.Pro246Leu
16 Male 26 CS c.382A>G p.Lys128Glu d
17 Male 40 CS c.49C>T p.Gln17X
18 Male 17 CS c.49C>T p.Gln17X
19 Female 14 CS c.511C>T p.Gln171X
20 Male 8 CS/BRRS c.420_421insA p.His141ThrfsX39
21 Male 43 CS/BRRS c.441_442delGGinsA p.Ala148HisfsX5
22 Female 64 CS c.386G>A p.Gly129Glu
23 Female 47 CS c.401T>C p.Met134Thr d
24 Male 6 CS c.388C>T p.Arg130X d
25 Male 14 CS c.208C>G p.Leu70Val d
26 Male 13 ASD c.3G>T p.Met1Ile
27 Male 12 ASD c.3G>T p.Met1Ile
28 Female 4 ASD c.3G>T p.Met1Ile
29 Female 37 ASD c.3G>T p.Met1Ile
30 Male 8 CS/BRRS c.1003C>T p.Arg335X
31 Female 40 CS c.751_752delGG p.Gly251X d
32 Female 51 CS c.592_601del p.Met198LysfsX19 d
33 Male 39 CS/LD c.63412T>C d d
34 Male 9 CS c.491delA p.Lys164ArgfsX2 d
35 Male 15 CS c.26delT p.Ser10AlafsX14 d
36 Female 21 CS c.512_513insA p.Arg172GlufsX8 d
37 Male 39 CS/BRRS c.376G>C p.Ala126Pro d
38 Female 50 CS c.389G>A p.Arg130Gln d
39 Male 56 CS c.80-?_12121?del
40 Female 53 CS c.323T>C p.Leu108Pro
41 Female 62 CS/LD c.1027-2A>G
42 Male 12 BRRS c.389G>A p.Arg130Gln
43 Female 31 CS c.445C>T p.Gln149X d d
44 Female 39 CS c.388C>T p.Arg130X
45 Female 13 CS c.388C>T p.Arg130X
46 Male 41 CS c.1027-1G>A
47 Male 8 BRRS c.388C>T p.Arg130X
48 Female 40 BRRS c.388C>T p.Arg130X
49 Male 6 BRRS c.388C>T p.Arg130X
50 Female 41 CS/LD c.765dupA p.Glu256ArgfsX42
51 Female 67 CS c.106G>T p.Gly36X
52 Female 14 CS c.389G>A p.Arg130Gln
53 Male 50 LD c.388C>T p.Arg130X d
54 Female 10 BRRS c.930_931delTA p.Asp310GlufsX2
55 Male 48 BRRS c.930_931delTA p.Asp310GlufsX2 d d
56 Male 58 CS/LD c.534T>G p.Tyr178X
57 Female 49 CS c.493-?_12121?del d
58 Male 48 CS c.593T>A p.Met198Lys d
59 Female 31 CS c.73_74delTT p.Leu25AspfsX17 d
60 Male 5 BRRS c.445C>T p.Gln149X d
61 Male 50 BRRS c.1008C>G p.Tyr337X
62 Male 7 BRRS c.540C>A p.Tyr180X
(Continued)
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
CHEN ET AL 14.e13
TABLE E1. (Continued)
Patient no. Sex Age (y) Phenotype Genotype variation Protein variation Autoimmunity Lymphoid hyperplasia
63 Female 24 CS c.264T>A p.Tyr88X d
64 Female 30 CS c.491delA p.Lys164ArgfsX3 d
65 Female 51 CS c.802-2A>G
66 Female 30 CS c.445C>T p.Gln149X
67 Female 16 CS c.80-?_1641?del
68 Female 16 CS c.1008C>G p.Tyr337X
69 Male 19 BRRS c.389G>A p.Arg130Gln d
70 Male 5 unclassified c.80-?_12121?del d
71 Male 58 CS/LD c.534T>G p.Tyr178X d d
72 Female 68 CS c.334C>G p.Leu112_Lys164del d
73 Male 4 BRRS c.404T>A p.Ile135Lys
74 Female 37 CS c.1-?_1641?del
75 Female 39 CS c.141delG p.Asn48ThrfsX6
76 Female 59 CS c.1-?_1641?del
77 Male 36 CS c.654C>A p.Cys218X
78 Male 47 CS c.176C>G p.Ser59X
79 Male 65 CS c.640C>T p.Gln214X
BRRS, Bannayan-Riley-Ruvalcaba syndrome; CS, Cowden syndrome; LD, Lhermitte-Duclos disease.
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TABLE E2. Characteristics of the total PHTS group and subgroups that have been used to determine hematology and lymphocyte
subset analysis
Patient group No. Age (mean 6 SD)
Patients with PHTS, all 79 34.05 6 20.00
Female/male sex 40/39
Adult subgroup for hematology analysis*
Patients with PHTS 51 34.43 6 21.32
Female/male sex 22/29
Control subjects 235 38.86 6 13.31
Female/male sex 132/103
Adult subgroup for lymphocyte subset analysis
Patients with PHTS 12 45.00 6 14.36
Female/male sex 6/6
Control subjects 19 41.95 6 11.90
Female/male sex 12/7
*Data are presented in Fig 1, C.
Data are presented in Fig 1, E.
Patients originated from the community and tertiary referral centers of North America and Europe and were partially recruited through cohorts that have been previously
described (Heindl et al,E1 Tan et al,E10 and Heald et alE11). In a subgroup of patients, peripheral blood or archived formalin-fixed, paraffin-embedded gastrointestinal tissue was
analyzed. Endoscopy was performed as part of routine clinical procedures. Healthy blood donors with similar age and sex distribution served as blood count control subjects
(n 5 235). Similarly, healthy control subjects served as FACS controls for peripheral blood lymphocyte subsets.
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